Search research articles
Contact Us
Filters
Showing results (1-10 of 75) with videos related to
Page
of 8
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
February 18, 2011
Importance of accurate HER2 testing in patients with metastatic breast cancer
Ana Maria Gonzalez-Angulo
Clinical Advances in Hematology & Oncology : H&O
|
October 18, 2012
The importance of accuracy in HER2 testing
Ana Maria Gonzalez-Angulo
Expert Opinion on Therapeutic Targets
|
January 14, 2012
Targeting the PI3K signaling pathway in cancer therapy
Chandra Bartholomeusz, Ana Maria Gonzalez-Angulo
Ochsner Journal
|
July 24, 2012
The role of chemotherapy in colon cancer
Ana Maria Gonzalez-Angulo, Jyotsna Fuloria
Clinical Advances in Hematology & Oncology : H&O
|
December 22, 2009
HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?
Mariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Expert Opinion on Investigational Drugs
|
September 22, 2012
Everolimus in the treatment of hormone receptor-positive breast cancer
Mariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
The Oncologist
|
March 26, 2014
Implications of functional proteomics in breast cancer
Young Kwang Chae, Ana Maria Gonzalez-Angulo
Cancer Genomics & Proteomics
|
September 20, 2012
Breast cancer and metastasis: on the way toward individualized therapy
Adriana Priscila Trapé, Ana Maria Gonzalez-Angulo
Nature Reviews. Clinical Oncology
|
January 9, 2013
Breast cancer in 2012: New drugs, new knowledge, new targets
Mariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Current Treatment Options in Oncology
|
December 11, 2013
Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future
Ishwaria M Subbiah, Ana Maria Gonzalez-Angulo
Page
of 8
Search research articles
Search
Showing results (1-10 of 75) with videos related to
Sort By:
Page
of 8
Clinical Advances in Hematology & Oncology : H&O
|
February 18, 2011
Importance of accurate HER2 testing in patients with metastatic breast cancer
Ana Maria Gonzalez-Angulo
Clinical Advances in Hematology & Oncology : H&O
|
October 18, 2012
The importance of accuracy in HER2 testing
Ana Maria Gonzalez-Angulo
Expert Opinion on Therapeutic Targets
|
January 14, 2012
Targeting the PI3K signaling pathway in cancer therapy
Chandra Bartholomeusz, Ana Maria Gonzalez-Angulo
Ochsner Journal
|
July 24, 2012
The role of chemotherapy in colon cancer
Ana Maria Gonzalez-Angulo, Jyotsna Fuloria
Clinical Advances in Hematology & Oncology : H&O
|
December 22, 2009
HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?
Mariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Expert Opinion on Investigational Drugs
|
September 22, 2012
Everolimus in the treatment of hormone receptor-positive breast cancer
Mariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
The Oncologist
|
March 26, 2014
Implications of functional proteomics in breast cancer
Young Kwang Chae, Ana Maria Gonzalez-Angulo
Cancer Genomics & Proteomics
|
September 20, 2012
Breast cancer and metastasis: on the way toward individualized therapy
Adriana Priscila Trapé, Ana Maria Gonzalez-Angulo
Nature Reviews. Clinical Oncology
|
January 9, 2013
Breast cancer in 2012: New drugs, new knowledge, new targets
Mariana Chavez-MacGregor, Ana Maria Gonzalez-Angulo
Current Treatment Options in Oncology
|
December 11, 2013
Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future
Ishwaria M Subbiah, Ana Maria Gonzalez-Angulo
Page
of 8